Scott Z. Fields, MD, Bayer Pharmaceuticals explains Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients at Annual Meeting 2018
Advertisement
Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients
